Captrust Financial Advisors Increases Gilead Sciences Stake

Investment firm adds 29,500 shares to its position in the biopharmaceutical company.

Mar. 18, 2026 at 8:36am

Got story updates? Submit your updates here. ›

Captrust Financial Advisors, an investment management firm, has increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% in the third quarter. The firm now owns 1,908,126 shares of the biopharmaceutical company's stock, worth approximately $211.8 million.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. Captrust's increased stake in the company suggests the firm sees potential in Gilead's product portfolio and future growth prospects.

The details

According to a recent SEC filing, Captrust Financial Advisors added 29,500 shares of Gilead Sciences to its portfolio during the third quarter. This brings the firm's total position in Gilead to 1,908,126 shares, or approximately 0.15% of the company's outstanding stock.

  • Captrust Financial Advisors increased its Gilead Sciences holdings in the 3rd quarter of 2026.

The players

Captrust Financial Advisors

An investment management firm that has increased its stake in Gilead Sciences, Inc.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

Captrust Financial Advisors' increased investment in Gilead Sciences suggests the firm sees long-term potential in the biopharmaceutical company's product pipeline and market position. This move highlights the continued interest from institutional investors in Gilead Sciences as a leading player in the rapidly evolving pharmaceutical industry.